Related Experiment Videos
Thiazide prophylaxis of urolithiasis. A double-blind study in general practice
Acta Medica Scandinavica
|January 1, 1984
Summary
Hydrochlorothiazide significantly reduced new kidney stone formation in recurrent stone formers compared to placebo. This thiazide treatment also prolonged the stone-free interval for patients who did form new stones.
Area of Science:
- Nephrology
- Urology
- Pharmacology
Background:
- Recurrent kidney stone formation poses a significant health burden.
- Identifying effective preventative treatments is crucial for patient management.
Purpose of the Study:
- To evaluate the efficacy of hydrochlorothiazide in preventing new stone formation in recurrent stone formers.
- To compare the effects of hydrochlorothiazide versus placebo over a median follow-up of 3 years.
Main Methods:
- A double-blind, randomized controlled trial involving 50 recurrent stone formers.
- Twice-daily administration of 25 mg hydrochlorothiazide compared to placebo.
- Assessment of new stone formation and stone-free intervals.
Main Results:
- Significantly fewer patients in the hydrochlorothiazide group formed new stones (p=0.05).
- Hydrochlorothiazide prolonged the stone-free interval in patients who did form stones (p<=0.01).
- The probability of remaining stone-free was 75% with thiazide versus 45% with placebo.
Conclusions:
- Twice-daily hydrochlorothiazide is effective in reducing new kidney stone formation.
- The benefits of hydrochlorothiazide appear independent of urinary calcium levels but may be less pronounced in hyperuricosuria.
- The study highlights the necessity of robust control groups in stone prevention research.